Dyne reports new one-year data from ACHIEVE trial of z-basivarsen in DM1
The company disclosed 6- and 12-month results from a pooled dose group and gave the baseline vHOT value for its 71-patient registrational cohort.
SEC filing
Latest
4 stories
Tuesday, September 29
Wednesday, July 29
Dyne reports Q2 2026 results as FDA accepts BLA for z-rostudirsen
Dyne's exon 51 DMD therapy gets priority review with a January 2027 PDUFA date, while the company advances DM1 and FSHD programs and reports $898.5 million in cash.
SEC filing
Wednesday, July 22
Dyne Therapeutics prices upsized $375 million stock offering at $20.50 a share
The neuromuscular disease drug developer expects to close the sale of 18.3 million shares on or about July 23, 2026, with proceeds earmarked to fund clinical programs into the second quarter of 2028.
SEC filing (3)